Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065073 | 0.90 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2543127 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27763578 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2543130 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3057977 | 0.88 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3059765 | 0.87 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3062468 | 0.87 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3057276 | 0.87 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3052632 | 0.86 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16180469 | 0.86 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | claimed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK12 | MAPK14 13/4885MAPK13 5/4885MAPK12 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.